-+ 0.00%
-+ 0.00%
-+ 0.00%

China Medical System wins China approval for ruxolitinib cream in atopic dermatitis

PUBT·09/03/2026 09:55:43
Listen to the news
China Medical System wins China approval for ruxolitinib cream in atopic dermatitis
  • China Medical System unit Dermatology Medical won NMPA clearance for ruxolitinib phosphate cream Bairutuo to treat mild-to-moderate atopic dermatitis.
  • Label covers non-immunocompromised patients aged 2 and older when other topical therapies are inadequate or not advisable.
  • Approval followed priority review; a China Phase III trial showed IGA 0/1 at week 8 of 63% vs 9.2% for placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12318921), on September 03, 2026, and is solely responsible for the information contained therein.